Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials
Morten Schmidt, Henrik Toft Sørensen, Lars Pedersen
Topics & Concepts
MedicineEtoricoxibDiclofenacMeloxicamEtodolacCelecoxibMaceAdverse effectInternal medicineHazard ratioConfidence intervalRofecoxibNaproxenPharmacologyAnesthesiaPercutaneous coronary interventionCyclooxygenaseMyocardial infarctionPathologyAlternative medicineEnzymeBiochemistryChemistryInflammatory mediators and NSAID effectsOpioid Use Disorder TreatmentPharmacovigilance and Adverse Drug Reactions